Skip to main content
padlock icon - secure page this page is secure

Open Access Downregulation of SMAD2, 4 and 6 mRNA and TGF Receptor I mRNA in Lesional and Non-lesional Psoriatic Skin

Download Article:
(PDF 574 kb)
Transforming growth factor beta (TGF) has been suggested to be an effective inhibitor of the increased keratinocyte proliferation in psoriasis. Three TGF isoforms are described (TGF1, 2 and 3), signalling via a heteromeric receptor complex of TGFRI and TGFRII. Receptor binding activates SMAD2, 3 and 4, which translocate into the nucleus and regulate TGF-responsive genes. SMAD6 and 7 proteins represent a negative feedback loop inhibiting the TGF-SMAD signalling pathway. As TGF1 overexpression inhibits keratinocyte proliferation, the aim of this study was to investigate with real-time RT-PCR the expression of TGF1, 2 and 3, TGFRI and TGFRII and SMAD2, 3, 4, 6 and 7 in lesional and non-lesional psoriatic skin from 13 patients with chronic plaque-type psoriasis as compared to skin from 10 healthy subjects. The study data demonstrate significantly downregulated TGFRI and SMAD2, 4 and 6 mRNA expression in lesional and non-lesional psoriatic skin. SMAD7 mRNA expression was significantly decreased in lesional psoriatic skin compared with both non-lesional psoriatic skin and healthy skin. A significant TGF3 and TGFRII mRNA upregulation exclusively in non-lesional psoriatic skin but no significant difference in the expression of TGF1 and 2 was found. The results of this study suggest that the expression of TGF isoforms, receptors and SMADs may be involved in the increased proliferation of keratinocytes in psoriatic skin.

27 References.

No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: June 1, 2009

More about this publication?
  • Acta Dermato-Venereologica is a bi-monthly international peer-reviewed journal for clinical and experimental research in the field of dermatology and venereology.

    It was founded in 1920 by Johan Almqvist and edited during 1936-1969 by Sven Hellerström. Since 1970, the journal has been published for the Society for the Publication of Acta Dermato-Venereologica on a non-profit basis.

    Acta Dermato-Venereologica publishes high-quality manuscripts in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as short Letters to the Editor to stimulate debate and to disseminate important clinical observations. Acta Dermato-Venereologica has rapid publication times and is amply illustrated with a large number of colour photographs to enhance understanding.

    Acta Dermato-Venereologica covers inter alia:

    • ~ Atopic dermatitis and contact allergy
    • ~ Facial dermatoses and adnexal disorders
    • ~ New treatments
    • ~ Psoriasis and genodermatoses
    • ~ Psychodermatology
    • ~ Sexually transmitted diseases
    • ~ Skin biology and inflammation
    • ~ Skin cancer and pigmentation
    • ~ Skin immunology and lymphoma
    • ~ Urticaria and itch

    Extensive papers, proceedings from congresses and symposia are printed as supplements to the journal. Announcements concerning pertinent dermatological meetings and books received are also published.
    Readership: Doctors and scientists interested in dermatology, skin biology and venereology.

    Acta Dermato-Venereologica has an impact factor of 3.007.

    Issues between 1998 up to 2005 can be found at

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • The impact factor keeps rising!
  • For reviewers
  • Contact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more